Roche remains committed to its amylin analog, petrelintide, despite recent clinical data that fell short of expectations. The company reported a modest 9% weight reduction in patients at 42 weeks in a placebo-controlled trial, which disappointed analysts and investors alike.
The Challenge of Weight Loss Expectations
In a recent earnings call, Roche CEO Thomas Schinecker defended petrelintide, emphasizing its unique value proposition for patients who prioritize tolerability over aggressive weight loss. “If you don’t want side effects, you can take a highly tolerable amylin drug,” he stated, highlighting the challenges some patients face with other weight-loss medications that may lead to discontinuation.
Analysts had anticipated results that would demonstrate at least a 12% weight reduction, using Eli Lilly’s competing amylin drug, eloralintide, which achieved a 16% weight loss in its own Phase 2 study as a benchmark. However, Schinecker acknowledged the limitations in comparing results across different trials.
A Focus on Tolerability
Schinecker pointed out that only a small percentage of patients—4.8% at the highest dose—dropped out of the petrelintide study due to side effects, a figure comparable to the 4.9% dropout rate in the placebo group. This low rate of discontinuation underscores petrelintide’s favorable tolerability profile, an aspect Schinecker believes is critical in the maintenance of weight loss and in combination treatments.
In the face of the overwhelming efficacy seen with GLP-1 drugs, which may lead to weight loss exceeding 20%, Roche insists that a place remains for amylin drugs within obesity treatment. For patients wary of side effects, petrelintide offers a safer alternative.
Mixed Financial Results
Roche’s financial performance for the first quarter of 2026 showed a revenue of CHF 14.72 billion ($18.77 billion), marking a 5% decline from the previous year. The company attributed this dip to the strengthening Swiss franc against other currencies, particularly the U.S. dollar. In constant currency terms, however, Roche’s sales grew by 6%, indicating underlying growth despite currency fluctuations.
The company’s top-performing product during this period was the multiple sclerosis treatment Ocrevus, generating nearly CHF 1.7 billion ($2.17 billion) in sales, reflecting a 6% year-over-year increase. Other significant contributors included the hemophilia A medication Hemlibra and the eye injection Vabysmo, which brought in CHF 1.2 billion ($1.53 billion) and CHF 1.02 billion ($1.3 billion), respectively.
Future Prospects for Amylin Drugs
Despite the disappointing results from the petrelintide trial, Schinecker remains optimistic about the future of amylin drugs in the obesity treatment landscape. He reiterated that while some patients may seek substantial weight loss, others prioritize a more tolerable approach to treatment.
“The best benefit that petrelintide has is its tolerability,” he remarked, positioning the drug as a viable option for those who need a gentler approach to weight management.
Takeaway Insights
- Roche’s petrelintide demonstrates a 9% weight reduction in recent trials, emphasizing tolerability as its primary advantage.
- CEO Thomas Schinecker advocates for amylin drugs as a suitable option for patients who are sensitive to side effects.
-
Financial results show a slight decline in revenue, yet Roche’s sales grew when adjusted for currency fluctuations.
-
Ocrevus remains Roche’s leading product, complemented by strong performances from Hemlibra and Vabysmo.
Conclusion
Roche’s commitment to petrelintide reflects a nuanced understanding of patient needs in the obesity treatment arena. As the market evolves, the emphasis on tolerability may indeed carve out a niche for amylin drugs, balancing the scales between efficacy and patient comfort.
Read more → www.biospace.com